Clinical trials: Inflammation Eye Pain
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Postoperative Ocular Inflammation, Postoperative Ocular Pain
A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery
This study is designed to evaluate the safety and efficacy of TRIESENCE® (triamcinolone acetonide injectable suspension) in patients undergoing ophthalmic procedures.
- Trial name
- NCT07832552
- Testing
- TRIESENCE (triamcinolone acetonide injectable suspension)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Harrow Inc
Post Surgical Ocular Inflammation and Pain
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
- Trial name
- NCT02793817
- Testing
- KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- Where
- 35 sites in United States
- Volunteers
- 520 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Inflammation, Pain
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT01298752
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Bausch & Lomb Incorporated
Vitreoretinal Surgery, Ocular Inflammation
Dextenza in the Post-op Management of Vitreoretinal Surgeries
This study will assess the control of inflammation at days 1, 7, 14, and 21 days following the vitreoretinal surgical procedure analyzing two randomized study arms: Intracanalicular dexamethasone insert group or topical steroid…
- Conditions
- Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain, Post-Operative Inflammation
- Trial name
- NCT04371445
- Testing
- Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Corneal Endothelial Cell Loss, Ocular Pain
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery.
- Conditions
- Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
- Trial name
- NCT02128113
- Testing
- Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
- Where
- 15 sites in United States
- Volunteers
- 307 people
- Sponsor
- Biogen
Inflammation, Pain
Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery
The primary objective of this study is to assess the efficacy and safety of 2 concentrations of RX-10045 ophthalmic solution, 0.05% and 0.1%, compared to placebo for the treatment of ocular inflammation and pain in subjects…
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02329743
- Testing
- RX-10045
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- A.T. Resolve SARL
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections
This is an investigator initiated prospective open-label, within-patient, masked, randomized study in patients with neovascular AMD, DME, or RVO undergoing bilateral anti-VEGF injections.
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- DETeR (NCT04563299)
- Testing
- Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Retina Vitreous Associates of Florida
Corneal Edema, Corneal Defect
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery
Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg insert following corneal transplant surgery (PKP, DSEK, DMEK) as compared to topical prednisolone acetate 1%.
- Conditions
- Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty
- Trial name
- NCT04521140
- Testing
- Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Nicole Fram M.D.
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
Rheumatoid Arthritis
EMDR for Persistent Pain in RA
Rationale: Around 20% of rheumatoid arthritis (RA) patients have persistent pain, despite having well-controlled disease activity.
- Trial name
- NCT05941559
- Testing
- EMDR
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Medisch Spectrum Twente
Pterygium, Pain
Effect of Bromfenac on Pain Related to Pterygium Surgery
To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution (bromfenac) 0.1% dosed twice daily for the treatment of ocular inflammation and pain after pterygium excision with amniotic membrane transplantation(AMT).
- Trial name
- NCT04022811
- Testing
- 0.1% bromfenac
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Inflammation, Pain
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02508337
- Testing
- XG-102
- Where
- United States
- Volunteers
- 309 people
- Sponsor
- Xigen SA
Cataract
Nepafenac 0.3% Two Study
The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
- Trial name
- NCT01318499
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle 0.3%
- Where
- United States
- Volunteers
- 1,342 people
- Sponsor
- Alcon Research
Inflammation Eye Pain, Postoperative Cataract
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
- Trial name
- OPTIMIZE-1 (NCT05147233)
- Testing
- OCS-01, Vehicle
- Where
- 25 sites in United States
- Volunteers
- 241 people
- Sponsor
- Oculis
Corneal Edema, Corneal Defect
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
- Conditions
- Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain
- Trial name
- NCT05626478
- Testing
- Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Nicole Fram M.D.
Pain, Inflammation
Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
This is an efficacy study of Bromfenac Ophthalmic Solution in cataract surgery.
- Conditions
- Pain, Inflammation, Cataract
- Trial name
- NCT01367249
- Testing
- Bromfenac Ophthalmic Solution
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Bausch & Lomb Incorporated
Inflammation and Pain Following Ocular Surgery
RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.
- Trial name
- NCT02065375
- Testing
- Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Biogen
Anterior Chamber Inflammation, Ocular Pain
A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery
A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal transplant or Cataract surgery
- Conditions
- Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect
- Trial name
- NCT04975971
- Testing
- Dextenza 0.4Mg Ophthalmic Insert
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Nicole Fram M.D.
Pain, Inflammation
Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract
This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two…
- Trial name
- NCT03496467
- Testing
- Nepafenac PPDS
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mati Therapeutics Inc.